Vistagen Therapeutics, Inc. (VTGN)

Market Cap	60.94M
Revenue (ttm)	486,000
Net Income (ttm)	-51.42M
Shares Out	29.16M
EPS (ttm)	-1.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	176,909
Open	2.030
Previous Close	1.960
Day's Range	2.030 - 2.160
52-Week Range	1.900 - 4.210
Beta	0.69
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 17, 2025

About VTGN

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN
• Website: https://www.vistagen.com

Financial Performance

In 2024, Vistagen Therapeutics's revenue was $486,000, a decrease of -54.32% compared to the previous year's $1.06 million. Losses were -$51.42 million, 75.1% more than in 2023.